ICIs(Immune checkpoint inhibitors)

DRUG2 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Yongxu Jia

Conditions

Gastric Cancer, Gastroesophageal Junction CancerHCCImmune Checkpoint Inhibitors (ICIs)RetreatmentSecond-line

Phase 2

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

RecruitingNCT06413017

Tianjin Medical University Cancer Institute and HospitalHCC

Start: 2023-08-31End: 2025-12-31Target: 30Updated: 2024-05-14

Unknown Phase

Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study

Not yet recruitingNCT06814548

Yongxu JiaGastric Cancer, Gastroesophageal Junction Cancer, Immune Checkpoint Inhibitors (ICIs), Retreatment +1

Start: 2025-02-10End: 2025-05-31Target: 200Updated: 2025-02-07